harte-hanks inc. - HHS

HHS

Close Chg Chg %
3.34 -0.03 -0.90%

Closed Market

3.31

-0.03 (0.90%)

Volume: 658.00

Last Updated:

Dec 24, 2025, 1:00 PM EDT

Company Overview: harte-hanks inc. - HHS

HHS Key Data

Open

$3.32

Day Range

3.31 - 3.32

52 Week Range

2.33 - 5.59

Market Cap

$24.77M

Shares Outstanding

7.41M

Public Float

5.90M

Beta

-0.17

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.74

Yield

0.00%

Dividend

$0.09

EX-DIVIDEND DATE

Feb 26, 2016

SHORT INTEREST

N/A

AVERAGE VOLUME

8.81K

 

HHS Performance

1 Week
 
-1.49%
 
1 Month
 
-12.20%
 
3 Months
 
-10.54%
 
1 Year
 
-38.48%
 
5 Years
 
29.80%
 

HHS Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About harte-hanks inc. - HHS

Harte-Hanks, Inc. is a global customer experience company operating in three business segments: Marketing Services, Customer Care, and Fulfillment & Logistics Services. The company's mission is to partner with clients to provide them with a robust customer-experience, or CX, strategy, data-driven analytics and actionable insights combined with seamless program execution to better understand, attract, and engage their customers. Its services include strategic planning, data strategy, performance analytics, creative development, and execution, technology enablement, marketing automation, B2B and B2C e-commerce, cross-channel customer care, and product, print, and mail fulfillment. The company was founded in 1923 and is headquartered in Chelmsford, MA.

HHS At a Glance

Harte-Hanks, Inc.
1 Executive Drive
Chelmsford, Massachusetts 01824
Phone 1-512-434-1100 Revenue 185.24M
Industry Miscellaneous Commercial Services Net Income -30,297,000.00
Sector Commercial Services Employees 2,003
Fiscal Year-end 12 / 2025
View SEC Filings

HHS Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.203
Price to Book Ratio 1.747
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA 4.334
Enterprise Value to Sales 0.282
Total Debt to Enterprise Value 0.471

HHS Efficiency

Revenue/Employee 92,482.277
Income Per Employee -15,125.811
Receivables Turnover 4.647
Total Asset Turnover 1.518

HHS Liquidity

Current Ratio 1.526
Quick Ratio 1.526
Cash Ratio 0.283

HHS Profitability

Gross Margin 16.435
Operating Margin 4.137
Pretax Margin -20.478
Net Margin -16.355
Return on Assets -24.835
Return on Equity -145.848
Return on Total Capital -65.457
Return on Invested Capital -70.379

HHS Capital Structure

Total Debt to Total Equity 113.403
Total Debt to Total Capital 53.14
Total Debt to Total Assets 21.784
Long-Term Debt to Equity 96.178
Long-Term Debt to Total Capital 45.069
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Harte-hanks Inc. - HHS

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
194.60M 206.28M 191.49M 185.24M
Sales Growth
+10.00% +6.00% -7.17% -3.26%
Cost of Goods Sold (COGS) incl D&A
162.74M 173.20M 161.77M 154.80M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
2.56M 2.73M 4.24M 4.38M
Depreciation
2.56M 2.73M 3.40M 3.50M
Amortization of Intangibles
- - 837.00K 885.00K
-
COGS Growth
+3.93% +6.43% -6.60% -4.31%
Gross Income
31.86M 33.08M 29.72M 30.44M
Gross Income Growth
+56.77% +3.83% -10.15% +2.44%
Gross Profit Margin
+16.37% +16.04% +15.52% +16.43%
2021 2022 2023 2024 5-year trend
SG&A Expense
17.86M 17.97M 20.67M 22.78M
Research & Development
- - - -
-
Other SG&A
17.86M 17.97M 20.67M 22.78M
SGA Growth
-17.02% +0.63% +15.04% +10.20%
Other Operating Expense
- - - -
-
Unusual Expense
- (3.64M) 5.69M 43.08M
EBIT after Unusual Expense
17.64M 15.11M 3.36M (35.41M)
Non Operating Income/Expense
(477.00K) 4.64M (5.28M) (2.33M)
Non-Operating Interest Income
- - - 135.00K
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- 903.00K 438.00K 187.00K
Interest Expense Growth
- - -22.42% -51.50%
-
Gross Interest Expense
- 903.00K 438.00K 187.00K
Interest Capitalized
- - - -
-
Pretax Income
16.26M 19.31M (1.92M) (37.93M)
Pretax Income Growth
+188.80% +18.78% -109.94% -1,876.76%
Pretax Margin
+8.36% +9.36% -1.00% -20.48%
Income Tax
1.29M (17.46M) (349.00K) (7.64M)
Income Tax - Current - Domestic
484.00K 834.00K 254.00K 428.00K
Income Tax - Current - Foreign
804.00K 1.55M 871.00K 1.21M
Income Tax - Deferred - Domestic
- (19.84M) (1.56M) (9.18M)
Income Tax - Deferred - Foreign
- - 82.00K (104.00K)
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - (1.86M)
-
Consolidated Net Income
13.11M 36.78M (1.57M) (30.30M)
Minority Interest Expense
- - - -
-
Net Income
13.11M 36.78M (1.57M) (30.30M)
Net Income Growth
+874.09% +180.45% -104.27% -1,829.75%
Net Margin Growth
+6.74% +17.83% -0.82% -16.36%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
13.11M 36.78M (1.57M) (30.30M)
Preferred Dividends
- - 496.00K 1.38M
-
Net Income Available to Common
12.62M 35.40M (1.57M) (30.30M)
EPS (Basic)
1.8549 4.9846 -0.2148 -4.1543
EPS (Basic) Growth
+647.98% +168.73% -104.31% -1,834.03%
Basic Shares Outstanding
6.80M 7.10M 7.31M 7.29M
EPS (Diluted)
1.7502 4.7467 -0.2148 -4.1543
EPS (Diluted) Growth
+617.05% +171.21% -104.53% -1,834.03%
Diluted Shares Outstanding
7.21M 7.46M 7.31M 7.29M
EBITDA
16.56M 17.84M 13.28M 12.05M
EBITDA Growth
+586.16% +7.72% -25.52% -9.30%
EBITDA Margin
+8.51% +8.65% +6.94% +6.50%

Snapshot

Average Recommendation BUY Average Target Price 17.50
Number of Ratings 1 Current Quarters Estimate N/A
FY Report Date N/A Current Year's Estimate N/A
Last Quarter’s Earnings -0.217 Median PE on CY Estimate N/A
Year Ago Earnings -3.548 Next Fiscal Year Estimate N/A
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates N/A N/A N/A N/A
Mean Estimate N/A N/A N/A N/A
High Estimates N/A N/A N/A N/A
Low Estimate N/A N/A N/A N/A
Coefficient of Variance N/A N/A N/A N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 1 1
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Harte-hanks Inc. - HHS

Date Name Shares Transaction Value
Dec 16, 2025 Genevieve Claire Combes Director 27,861 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $3.23 per share 89,991.03
Mar 6, 2025 Robert T. Wyman General Counsel 8,334 Other acquisition or disposition Non-derivative transaction at $5.01 per share 41,753.34
Mar 6, 2025 Robert T. Wyman General Counsel 27,847 Other acquisition or disposition Non-derivative transaction at $5.01 per share 139,513.47
Mar 6, 2025 Robert T. Wyman General Counsel 26,070 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $5.01 per share 130,610.70

Harte-Hanks Inc. in the News